Released by AnaSpec

Released on: June 17, 2008, 9:59 am

Press Release Author: AnaSpec Inc.

Industry: Biotech

Press Release Summary: AnaSpec has introduced a new series of IHC validated
antibodies, Anti-CARMA/CARD/Bimp antibodies.

Press Release Body: San Jose, CA - Jun 17, 2008
AnaSpec has introduced a new series of IHC validated antibodies,
Anti-CARMA/CARD/Bimp antibodies.
CARMA proteins are scaffold molecules that belong to the membrane-associated
guanylate kinase-like (MAGUK) and the caspase-associated recruitment domain (CARD)
protein families. They play critical role in antigen receptor signaling pathways.1-4
CARMA-1 (CARD-11) CARMA-2 (CARD-14), and CARMA-3 (CARD-10) share homologous sequence
and functions but are found in different tissues. CARMA1 is predominantly located in
lymphoid tissue.5 CARMA-1 protein associates with lipid rafts1 and interacts with
Bcl10, that is required for activation of TCR induced NFkB signaling pathway.1,2,4
Specifically, CARMA-1 N-terminal CARD domain binds to Bcl10 CARD motif.5 It is also
essential for protein-induced IL-2 and INF-γ production.2 CARMA-2 is mostly
found in placenta.5 CARMA-2 protein induces NFκB activation; however, its
signaling pathway it is not yet known.5 CARMA-3 is most abundant in nonhematopoietic
cells.5 CARMA-3 protein physically associates with IKK complex and induces NFκB
activation via LPA signaling pathway.7 CARMA genes deactivation studies in mice
resulted in reduced immunoglobulin levels and absence of TCR-induced NFκB
activation.4,6,7 This suggests that CARMA mutations may lead to adaptive and innate
immunity malfunction.
Immunohistochemistry of these antibodies was performed by an anatomic pathologist on
formalin-fixed, paraffin-embedded human or mouse tissues. Table 1 summarizes the IHC
results. At least 22 different human or mouse tissues or cell types, including
positive and negative tissues were used for each antibody tested. Dilutions of the
antibodies at 2.5, 5, 10 and 20 ug/ml were tested, with the optimal concentration
found to be at 10 ug/ml. These antibodies, provided at 50 ug, are sufficient for at
least 5 IHCs. Moderate to strong staining with minimal background staining at the
expected target tissues were observed for the antibodies. A representative image
from a positively stained tissue is shown for each antibody. It shows the
localization of the antibody as the precipitated red signal, with a hematoxylin
purple nuclear counterstain.
Anti-CARMA Antibodies:
Anti-CARMA-1/CARD-11, human, Cat# 54982
Anti-CARMA-1/CARD-11, mouse, Cat# 54985
Anti-CARMA-2/CARD-14,human, Cat# 54983
Anti-CARMA-3/CARD-10,human, Cat# 54984
Anti-CARMA-3/CARD-10, mouse, Cat# 54987

Company Info
AnaSpec, Inc. is a leading provider of integrated proteomics solutions to
pharmaceutical, biotech, and academic research institutions throughout the world.
With a vision for innovation through synergy, AnaSpec focuses on three core
technologies: peptides, detection reagents (dyes, assay kits, & antibodies), and
combinatorial chemistry.
For more information, visit www.anaspec.com

REFERENCES
1. Gaide, O et al. Nat. Immunology 3: 836 (2002).
2. Hara, H. et al. JEM, 200, 1167 (2004).
3. Narayan, P. et al. Mol Cell Bio 26, 2327 (2006).
4. Egawa T. et al. Current Biology 13, 1252 (2003).
5. Grabiner, B. et al. Genes and Dev. 21, 984 (2007).
6. Newton, K. et al. Current Biology 13, 1247 (2003).
7. Stilo R. et al. J. Biol. Chem.279: 34323 (2004).



Web Site: http://www.anaspec.com

Contact Details: AnaSpec Inc.
2149 O\'Toole Ave.
San Jose, CA 95131
1-408-452-5055 (Tel)
1-408-452-5059 (Fax)
1-800-452-5530
ping@anaspec.com
www.anaspec.com